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Abstract 
In this study, our aim is to assess the role played by autophagy and its inhibition in the 
different PDAC cellular compartments, and its involvement in chemo-resistance using 
primary human pancreatic cancer-derived cells (PCC) and Cancer Associated Fibroblasts 
(CAF). Autophagy flux, as measured by LC3-I and -II in the presence of Chloroquine, showed 
a variable level in PCC and CAFs. We found no correlation between autophagy level and 
degree of tumor differentiation. Association of Chloroquine with gemcitabine, 5FU, 
oxaliplatin, irinotecan and docetaxel revealed that its effect on survival is cell- and drug-
dependent in vitro and in vivo. In addition, we demonstrated that autophagy in CAFs can 
play an important role in sensitizing PDAC to anticancer treatments since its inhibition 
increased the resistance of PCCs to gemcitabine. In conclusion, this work clearly shows a 
heterogeneity in the effect of Chloroquine and highlights a role of CAFs autophagy in 
sensitizing tumors to treatments. It also reveals that the role of autophagy is more complex 
than expected in PDAC as well as its sensitivity to treatments. 
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease due to early metastasis, 
rapid evolution, and strong chemoresistance [1]. PDAC cells show an extreme resistance to 
current therapeutic treatments, probably due to altered mechanisms of cell survival and 
metabolic pathways [2]. In PDACs, the abundant stroma produced by Cancer-Associated 
Fibroblasts (CAFs), act as a mechanical barrier against the effective delivery of 
chemotherapeutic agents [3]. In addition to the secreted ECM components, CAFs have been 
described to be important for cell survival and metastatic signaling, thereby promoting 
tumor growth and invasion. This is mainly carried out through the activation of basic cellular 
processes, such as autophagy [4]. However, the failure of Sonic Hedgehog (SHH) inhibitor 
vismodegib [5] and LOX inhibitor [6] in clinical trials suggests the need to revise this 
paradigm.  
 
Autophagy is a catabolic process of degrading organelles and macromolecules, to allow the 
recycling of energetic products [7]. Autophagy modulates cellular metabolism [8], and its 
increased rate has been associated with cancer development and aggressiveness [9]. This 
process is activated in response to stress, such as nutrient deprivation, in order to promote 
cell survival. Emerging evidences have shown that autophagy may play an important role in 
the regulation of chemoresistance to anti-tumoral treatments [10, 11]. However, the role of 
autophagy in the regulation of tumor development and drug resistance is still elusive. Many 
studies suggest that autophagy plays a protective role, favoring tumor development, rather 
than a suppressive function [12, 13]. However, it has been described that this process may 
have a tumor promoting or an inhibitory function depending on the tumor compartment in 
which it is activated [14]. So, this is why it is important to understand the role of autophagy 
in each tumor compartment separately. Drugs effectively inhibiting autophagy flux are 
available, one of the most efficient being the anti-malarial drug Chloroquine [15]. This drug is 
approved by the FDA and it inhibits autophagy at its late stages by preventing the lysosomal 
acidification [16].  
 
In this study, we show that the effect of the treatment of PDAC cells with chloroquine, in 
combination with five anticancer drugs, is tumor- and drug-dependent. Moreover, we show 
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that blocking autophagy in CAFs increases the resistance PDAC-derived cells to gemcitabine 
based chemotherapy.  
Results 
Autophagy levels heterogeneity in PDAC primary cell cultures and CAFs 
The role of autophagy in cancer is complex and varies among the tumors types and the stage 
of the disease [17]. With the aim to explore the role of this biological process in PDAC 
chemoresistance, we first evaluated autophagy in 10 PDAC primary cells (PCC) derived from 
PDTX (Patients Derived Tumor Xenografts). The microtubule-associated protein 1 light chain 
3-II (LC3-II), a mammalian orthologous of Atg8, is a specific autophagy marker largely utilized 
for measuring the autophagy level in cells and tissues [18]. We have measured the LC3II/LC3I 
ratio of PCCs grown under nutrient-rich conditions to evaluate their basal level of autophagy 
and we could observe that it varies widely between the cell lines (Figure 1A), thereby 
confirming the heterogeneity of autophagy rates between different pancreatic patient 
tumors. We then analyzed the association between autophagy levels of the PCC along with 
their differentiation score. We found no significant correlation between degree of 
differentiation of the PCCs and their autophagy levels (Figure 1B). Next, we have evaluated 
the autophagy occurring in three human pancreatic cancer-derived CAFs (CAF1, CAF2 and 
CAF3). Similarly, our results showed a variation of basal autophagy levels among the three 
different CAFs tested (Figure 1C, D). 
 
It has been previously described that autophagy is required for the development of PDAC 
established cell lines in xenografts [19]. Chloroquine is a lysosomotropic agent that inhibits 
auto-lysosomal clearance [20]and it has been previously described that in combination with 
other chemotherapeutic agents, Chloroquine enhances their anti-cancer effects in several 
tumor types [21, 22]. Hence, we have evaluated the effect of Chloroquine treatment in both 
primary PDAC derived cells and CAFs. First, we confirmed that Chloroquine could block the 
autophagic flux in our studied cells. This was carried out by treating 10 primaries PCCs and 3 
CAFs with 10 µM Chloroquine for 2 h and 4 h followed by measurement of LC3-II and LC3-I 
levels by western blot. Our results showed that Chloroquine treatment increased the ratio of 
LC3-II/LC3-I after 2 h and 4 h of treatment in all analyzed cells (Figure 2A and B). Then, we 
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tested the relative sensitivity of PCCs and CAFs to increasing concentrations of Chloroquine 
by measuring the percentage of viable cells at each concentration. Our results showed that 
the IC50 of primary PCCs tested showed a wide variability (from 50 to 500 µM), which 
confirmed a strong heterogeneity in the response to Chloroquine between different PDAC 
samples (Figure 2C). Similar results were obtained with the three CAFs tested (Figure 2D) 
which displayed an IC50 of 40 µM, 60 µM and 80 µM. 
 
Chloroquine treatment plays a cell-dependent role when combined with 
chemotherapeutic drugs in vitro  
Autophagy is a mechanism that is essential for cell survival in response to several types of 
stresses. In fact, when cancer cells are subjected to stress conditions, autophagy is activated 
in order to maintain the cellular homeostasis [23, 24]. On the contrary, it has been suggested 
that the impairment of autophagy can lead to tumorigenesis in PDAC [19]. Hence, we aimed 
to evaluate the tumor response to the autophagy flux inhibition by Chloroquine in 
combination with the five most common chemotherapeutic drugs used in the treatment of 
PDAC. This was carried out by treating 10 primary PCCs derived from PDTXs with increasing 
concentrations of gemcitabine (G), 5-Fluouracil (5FU), oxaliplatin (Ox), Irinotecan (Ir) and 
docetaxel (D), alone or in combination with 10 µM of Chloroquine. Then, we measured cell 
viability after 72 h of treatment. Surprisingly, our results demonstrated that the effect of 
combining Chloroquine with chemotherapy was drug and cell type dependent. Interestingly, 
whereas Chloroquine increased sensitivity of some cells to the treatment, other tended to 
be more resistant while others were found to be insensitive (Figure 3). Accordingly, no 
correlation was found between autophagy flux levels of PCCs and their sensitivity to each of 
the five chemotherapeutic drugs used (Table 1), indicating that a higher level of autophagy 
does not necessarily account for a better response to the chemotherapeutic drugs.  
 
Chloroquine influences the effect of gemcitabine on tumor growth in a cell-dependent 
manner in vivo 
Our in vitro results suggested that Chloroquine influences the effect of anticancer drugs in a 
cell- and drug-dependent manner. Therefore, we evaluated the effect of Chloroquine in vivo 
using three different PCCs selected according to their response to the combination of 
gemcitabine with Chloroquine, positive, negative or null (see Figure 3). Interestingly, the 
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effect of Chloroquine was consistent with the in vitro observations. It was insignificant in 
PCC3 xenograft, whereas it increased the sensitivity to Gemcitabine in PCC10 and increased 
the gemcitabine resistance in PCC1 (Figure 4). Altogether, our in vitro and in vivo results 
strongly suggest that Chloroquine may have no effect, or could increase or decrease the 
sensitivity of PCCs in a cell- and drug-dependent manner.  
 
Chloroquine treatment influences the chemoresistance of CAFs  
As mentioned above, autophagy may have a tumor promoting or an inhibitory role 
depending on the cell compartment in which it is activated [14]. Therefore, it is important to 
understand the role of autophagy in the resistance to the treatments in each tumor 
compartment separately. We have shown that autophagy occurring in cancer cells did not 
influence the efficacy of chemotherapy. Therefore, we aimed to assess the involvement of 
CAFs’ autophagy in the chemoresistance of PDAC-derived cells. First, we subjected CAFs 
treated or not with 10 µM of Chloroquine to increasing doses of gemcitabine and found that 
these treatments did not affect the viability of CAFs (Figure 5A). Then, we performed a co-
culture assay that allowed us to separate autophagy induction in CAFs from the one in PCCs. 
We co-cultivated CAFs previously treated with 10 µM of Chloroquine for 48 h with PCCs, and 
subjected them to increasing doses of gemcitabine for 24 h. Our results showed that under 
lower doses of gemcitabine (below 15 nM) the sensitivity of PCCs was not affected upon 
cultivation with Chloroquine-treated CAFs (Figure 5B). However, under higher doses of 
gemcitabine (60 nM or more), the percentage of cell viability was higher when PCCs were 
cultivated with Chloroquine-treated CAFs (Figure 5B). Hence, blocking autophagy in CAFs 
increased the resistance of PCCs to gemcitabine treatment, suggesting that autophagy in 
CAFs can contribute in sensitizing PDAC to chemotherapy. 
 
Discussion 
Autophagy is shown to be a mechanism that promotes cell survival or can act in parallel with 
cell death when it is inhibited [25]. Therefore, autophagy inhibitors combined with 
chemotherapies are widely used as a cancer treatment [26]. However, the study of the 
ability of autophagy inhibitors to overcome resistance to anticancer therapies raises many 
questions. In the present work, we show for the first time that autophagy levels in human 
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PDAC-derived cells are not correlated with tumor differentiation scores, suggesting that 
higher levels of autophagy are not correlated with a more differentiated and a less 
aggressive tumor phenotype. Furthermore, we found that blocking autophagy with 
Chloroquine, a commonly used inhibitor, may improve cancer therapies, but in a cell- and 
drug-dependent manner as presented in Figures 3 and 4. Despite supportive preclinical data 
for the combination of Chloroquine with gemcitabine [27], results here showed that in some 
cases there is no improvement of treatment efficacy by adding autophagy inhibitors 
compared to the single-agent therapy. This outcome raises concerns about the role of 
autophagy in cancer development. It has been proposed that autophagy is activated as a 
protective mechanism during chemotherapy, but it has also been implicated in the induction 
of autophagic cell death.  
 
Autophagy dependency and metabolic stress levels of tumour cells vary widely depending on 
the tumor type and progression stage [28]. Therefore, reliable measurements to predict 
tumour sensitivity to autophagy inhibition would be extremely useful for patient selection in 
clinical practice [29]. As it was previously described, the status of tumour suppressor p53 can 
affect Chloroquine efficacy, and this may explain the dual effect found after Chloroquine 
therapy. Moreover, other studies have observed that higher steady-state mitochondrial 
membrane potential values, representing mitochondrial stability, can predict cancer cell 
resistance to Chloroquine treatment [30]. Thus, it appears that, depending on cancer types 
and cell state, autophagy differently impacts the effect of anticancer drugs on cell survival. 
Numerous clinical trials in which Chloroquine is being used to treat patients with a range of 
cancer types are registered in clinical trial databases, although some few trials have been 
completed, so limited published data are available. Nevertheless, there are many in vivo 
research which supported our findings [31-36]. Possibly, in some PDAC cells the role played 
by autophagy can be anti-apoptotic but pro-apoptotic in other cell types, therefore the 
consequences of inhibiting the autophagic flux is dependent on the biology of the PDAC 
cells. 
 
Stroma in PDAC is composed mainly of CAFs and inflammatory cells. Previous studies have 
suggested that the stroma acts as a barrier influencing the delivery of chemotherapeutic 
compounds to the tumor [37]. Nevertheless, preclinical studies have demonstrated that 
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depletion of cancer-associated fibroblasts failed to improve the efficacy of therapies and, in 
contrary, resulted in an accelerated progression of the disease [6]. Here, we found that 
blocking autophagy in CAFs did not affect their viability upon gemcitabine treatment but, 
surprisingly, could increase the resistance of co-cultivated PDAC cells when subjected to high 
doses of the same drug (Figure 5B). Because in our experimental model both cancer cells and 
CAFs are not in direct contact therefore we assume that the only possibility to affect 
sensitivity to treatments is through released factors. Accordingly, several mechanisms, 
including release of the exosomes and secretion of soluble factors, have been attributed to 
CAFs for increasing the resistance to treatments. In this way, after autophagy inhibition we 
can suppose that both release of exosomes and secretion of soluble factors increased. 
Hence, it appears the CAFs autophagy is necessary to preserve the efficacy of gemcitabine 
over cancer cells and this is probably one mechanism responsible for the bi-therapy failure.  
In conclusion, we have demonstrated that inhibition of autophagic flux in PDAC-derived 
cells, using Chloroquine, influences the effect of the anticancer drugs in a cell- and drug-
dependent manner. Therefore, it will be necessary to identify the appropriate markers that 
will determine when the Chloroquine treatment will increase the sensitivity of PDAC to a 
specific anticancer drug. Finally, this work also demonstrates that autophagy in CAFs plays 
an important role in sensitizing PDAC to anticancer treatments. Finally, although this work 
clearly shows the very high heterogeneity in the effect of Chloroquine and highlights the 
importance of CAFs autophagy in sensitizing tumors to treatments, it also reveals that the 
role of autophagy in PDAC is more complex than expected regarding the development of the 
disease and regarding the response to treatments. 
 
Material and Methods 
Tumor Samples. Patients were recruited for this study under the Paoli Calmettes Institute 
clinical trial number 2011-A01439-32. After patients were informed, consent had been 
obtained, excess tissue samples from resected PDACs were collected for xenograft or cell 
lines procedures. The tumor tissue used for xenograft development was deemed excess to 
that required for the patient’s diagnosis and standard of care and treatment. Two types of 
samples were obtained, Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA) 
biopsies from patients with unresectable tumors, and tumoral tissues from patients 
9 
 
undergoing surgery. Each sample obtained from EUS-FNA was mixed with 100 µl of Matrigel 
(BD Biosciences) and injected in the upper right flank of a nude mouse (Swiss Nude Mouse 
Crl: NU(lco)-Foxn1nu, Charles River Laboratories). Each sample derived from surgery 
resection was fragmented, mixed with 100 µl of Matrigel (BD Biosciences) and implanted 
with a trocar (10 Gauge, Innovative Research of America, Sarasota, FL) in the subcutaneous 
right upper flank of an anesthetized and disinfected mouse. When tumors reached 1 cm3, 
mice were sacrificed and removed. Xenografts that failed to develop within 6 months were 
stopped. Patient anonymity was maintained by removing any information that could lead to 
the identification of the patient. Post-surgical anatomopathology reports were provided for 
specimens from each patient. Histopathologic evaluation was performed on 5-μm H&E-
stained sections of patient tumors and pathologists determined tumor differentiation score.  
 
Animal Experiments. All animal experiments were conducted in accordance with 
institutional guidelines and were approved by the “Plateforme de Stabulation et 
d’Expérimentation Animale” (PSEA, Scientific Park of Luminy, Marseille). Briefly, a total 
number of 10 human PDAC xenografts were established. Tumor specimens (100 mm3), from 
resected PDAC patients, were mixed with Matrigel (BD Biosciences) and implanted 
subcutaneously on the upper right flank of 5- to 6-week-old nude mice (Swiss Nude Mouse 
Crl: NU (lco)-Foxn1nu, Charles River Laboratories). Tumor size and body weights of all 
animals were measured weekly. All mice were divided into groups receiving injections of PCC 
alone (1 × 106 per mouse); PCCs treated with gemcitabine and PCCs receiving gemcitabine in 
combination with Chloroquine. Subcutaneous tumor measurements were undertaken using 
calipers and values were calculated as (length x width2)/2. Gemcitabine (Lilly) treatment was 
administered twice weekly (100 mg/kg; i.p.). Chloroquine was administered daily (50 mg/kg; 
i.p.) 
 
Immunoblotting. Protein extraction was performed, on ice, using total protein extraction 
buffer: 50 mM HEPES (pH 7.5), 150 mM NaCl, 20% SDS, 1 mM EDTA, 1 mM EGTA, 10% 
glycerol, 1% Triton, 25 mM NaF, 10 mM ZnCl2 and 50 mM DTT. Before lysis, protease 
inhibitor cocktail at 1:200 (Sigma-Aldrich; NUPR1340), 500 mM PMSF, 1 mM sodium 
orthovanadate and 1 mM β-glycerophosphate were added. Protein concentrations were 
measured using a BCA Protein Assay Kit (Pierce Biotechnology). Protein samples (80 mg) 
10 
 
were denatured at 95°C and subsequently separated by SDS-PAGE gel electrophoresis. After 
being transferred to nitrocellulose, the membrane was blocked with 1% BSA, and the 
samples were probed with primary antibody, followed by a horseradish peroxidase-coupled 
(HRP) secondary antibody. β-Tubuline antibody was used as a loading control. 
 
Cell Culture. For in vitro studies, tumor fragments were enzymatically digested with 
collagenase type V (Sigma) and trypsin/EDTA (Gibco, Life Technologies) and suspended in 
DMEM, supplemented with 1% (w/w) Penicillin/Streptomycin (Gibco, Life Technologies) and 
10% Fetal Bovine Serum (Lonza). After centrifugation, cells were re-suspended in Serum Free 
Ductal Media (SFD), adapted from Schreiber et al [38], at 37°C in a 5% CO2 incubator. Cells 
were deprived of antibiotics at least 48 h before performing tests.  
 
Cancer-associated fibroblasts (CAFs) were prepared by the outgrowth method. Fresh tissue 
was obtained from residual pancreatic adenocarcinoma specimens from patients undergoing 
primary surgical resection. All human samples were obtained in accordance with the policies 
and practices of the Paoli Calmettes Institute clinical trial number 2011-A01439-32. Briefly, 
tumor samples were minced and seeded in six-well plates containing 15% FCS/DMEM, L- 
glutamine (2 mmol/L), penicillin/streptomycin, and amphotericin. After 25 days, cells were 
able to grow out from the tissue clumps. Medium was changed every 3 days. All cells were 
maintained at 37°C in a humidified atmosphere of 5% CO2.  
 
Chemograms. Cell chemosensitivity was assessed using gemcitabine 5-fluorouracil (5-FU), 
oxaliplatin, docetaxel and irinotecan, and Chloroquine (Sigma). Five thousand cells per well 
were plated in 96-wells plates in SFD media. 24 h later the media was supplemented with 
increasing concentrations of drugs (0 to 1000 µM), and incubated for an additional 72 h 
period. Each experiment was done in triplicate and repeated at least two times. Cell viability 
was measured after incubation with the PrestoBlue reagent (Life Technologies) for 3 h, the 
following the PrestoBlue cell viability reagent protocol provided by the supplier.  
 
Co-culture. CAFs were seeded at a density of 2.5 × 105 cells per well in a 6-co-culture well. 
1.5 x 105 cells Pancreatic Cancer cells (PCC) were seeded in the insert well (0.4 micron). 24 h 
later, CAFs were either treated with 10 µM of Chloroquine or with vehicle. After 4 h 
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incubation, the transwells containing PCCs were added to the plate, which were previously 
treated with increasing concentrations of gemcitabine. After 48 h of co-culture, cells were 
trypsinized and their viability analyzed.  
 
Statistical Analysis. Results for continuous variables are expressed as means ± standard 
error of the mean (SEM). Overall comparisons of continuous variables were performed using 
the unpaired two-tailed Student’s t-test. All tests of significance were two-tailed and the 
level of significance was set at 0.05. All data are representative of at least two independent 
experiments. 
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Legend of Figures 
 
Figure 1. (A) Basal Autophagy was evaluated by proteolysis of LC3-II by western blot. (B) The 
bar graph indicates the ratio between LC3-II and LC3-I at basal state after β-tubulin 
normalization. Autophagy levels were estimated and compared with tumor grade 
differentiation. (C) Basal Autophagy was evaluated in three CAFs. (D) The bar graph indicates 
the ratio between LC3-II and LC3-I at basal state after β-tubulin normalization. Experiments 
were repeated at least 2 times. 
Figure 2. (A) PCCs treated with 10 µM Chloroquine for 2 h or 4 h, and were compared with 
control. The estimated ratio of LC3-II/LC3-I was calculated between 2 h and 4 h Chloroquine 
treatment and basal state. (B) Three different CAFs were treated with 10 µM Chloroquine for 
2 h and 4 h, and the ratio of LC3-II/LC3-I was compared with control. (C) PDAC-derived 
primary cells were treated with increasing concentrations of Chloroquine and the cells 
viability were measured after 72 h of treatment. (D) CAFs were treated with increasing 
concentrations of Chloroquine and the cells viability were measured after 72 h of treatment. 
Error bars ± SEM; n = 3 per group. Experiments were repeated at least 2 times. 
Figure 3. PDAC-derived cells response to chemotherapy in vitro. Each primary cell line was 
treated with increasing concentrations (from 0 to 1000 μM) of gemcitabine (G), docetaxel 
(D), 5-Fluouracil (5FU), Oxaliplatin (Ox) and Irinotecan (Ir) alone or in combination with 10 
μM Choloroquine. Cell survival was measured after 72 h of treatment. The profile of 
sensitivity was obtained for each drug and the IC50 in response to each drug, with or without 
Chloroquine, is presented in the bar graphs relative to control. 
Figure 4. PCCs xenografts were treated with vehicle or gemcitabine alone or in combination 
with Chloroquine (50 mg/kg/day) after tumors attain a volume of 200 mm3. The tumor 
volume was monitored every 5 days. Error bars ± SEM; n=5 per group. *P<0.05 compared to 
Chloroquine treated.  
Figure 5. (A) Evaluation of the CAFs viability under increasing doses of gemcitabine in cells 
previously treated or non-treated treated with 10 µM of Chloroquine. (B) Proliferation of 
PCC3 co-cultured with CAFs previously treated or not treated with 10 μM Chloroquine for 48 
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h. PCCs were added to the upper part of the transwells and were incubated with increasing 
concentrations of gemcitabine for 24 h. Error bars ± SEM; n = 3 per group. *P<0.05 
compared to control. Experiments were repeated at least 2 times. 
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Table 1 
 
 G G+CQ D D+CQ Ir Ir+CQ 5FU 5FU+CQ Ox Ox+CQ 
R2 LC3II/LC3I 0.04 0.008 0.12 0.12 0.0008 0.01 0.04 0.04 0.44 0.11 
 
Linear regression was calculated between the IC50 for each treatment and levels of basal autophagy. 
gemcitabine (G), docetaxel (D), 5-Fluouracil (5FU), Oxaliplatin (Ox) and Irrinotecan (Ir) alone or in combination 
with Choloroquine (CQ). 
 
 
 
 
 
 
 
 





